Armored cells take on tough lymphoma in early trial
NCT ID NCT07368270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of immune cell therapy called anti-PD1 armored CD19 CAR-T cells in 30 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are designed to better attack cancer and resist exhaustion. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-PD1 armored CD19 CAR-T cells
What this could lead to
If successful, this could lead to a more effective treatment for hard-to-treat lymphoma by helping the immune system fight cancer longer.
What could go wrong
This is an early Phase 1 trial with only 30 people, so safety and effectiveness are not yet proven. Side effects like cytokine release syndrome or nerve problems are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••